Connect Biopharma Reports Positive Top-Line Results from the Global Phase II Clinical Trial of CBP-201 in Patients with Moderate-to-Severe Atopic Dermatitis

Connect Biopharma Holdings Limited reported positive topline results from the global Phase II clinical trial of CBP-201 administered subcutaneously to adult patients with moderate-to-severe atopic dermatitis.